PMC:7594251 / 38215-38378
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T21500 | 123-130 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T279 | 5-8 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T280 | 84-87 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T383 | 123-130 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T384 | 142-148 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
| T385 | 151-155 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T265 | 0-163 | Sentence | denotes | This has been done mainly via the Fragment Based Drug Design (FBDD) approach, which has two sub-approaches: target- (i.e., protein) based, or ligand- (drug) based. |